YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced that based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company's management, for the year ended 31 December 2021, the Group is expected to record a net loss attributable to the parent company (taking into account of convertible bonds) of approximately RMB 546 million to approximately RMB 630 million, as compared to the year ended 31 December 2020, the net profit attributable to the parent company (taking into account of convertible bonds) was approximately RMB 839 million (representing a decrease of approximately 165% to 175%). For the year ended 31 December 2021, the Group is expected to record a net loss attributable to the parent company (without taking into account of convertible bonds) of approximately RMB 384 million to approximately RMB 443 million, as compared to the year ended 31 December 2020, the net profit attributable to the parent company (without taking into account of convertible bonds) was approximately RMB 590 million (representing a decrease of approximately 165% to 175%).